The Cancer Letter wins investigative, design awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Letter won four 2019 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:

  • Investigative Journalism, Newsletter/Trade Publications, first place, for “When Surgical Innovation Kills,” by Matthew Ong
  • Front Page Design, Newsletter/Trade Publications, first place, by Jacqueline Ong and Katherine Goldberg
  • Photo Illustration, Newsletter/Trade Publications, first place, by Katherine Goldberg
  • Series, Newsletter/Trade Publications, finalist, for “From Rhetoric to Harm,” by Paul Goldberg and Matthew Ong

Ong has won six Dateline Awards over the past five years. This is the third time Ong has won a first-place Dateline Award for his investigative work on minimally invasive surgery and cancer-related outcomes.

Ong’s series has also received awards from six organizations, including the National Press Club, the national Society of Professional Journalists, and the National Institute for Health Care Management (The Cancer Letter, How Medical Devices do Harm, 2014-2017; When Surgical Innovation Kills, 2018-2019).

This is the second consecutive year The Cancer Letter has won first-place design awards.

Here are a few of The Cancer Letter’s award-winning covers published in 2018:

TCL44-43 copy
TCL44-30 copy
TCL44-06 copy
TCL44-16 copy
TCL44-28 copy

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login